Hideki Garren - Mar 15, 2023 Form 4 Insider Report for PROTHENA CORP PUBLIC LTD CO (PRTA)

Role
Chief Medical Officer
Signature
/s/ Michael Malecek, as attorney-in-fact for Hideki Garren
Stock symbol
PRTA
Transactions as of
Mar 15, 2023
Transactions value $
-$282,136
Form type
4
Date filed
3/17/2023, 09:30 PM
Previous filing
Mar 3, 2023
Next filing
Jun 14, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PRTA Ordinary Shares, par value $0.01 per share Options Exercise $299K +12K $24.90 12K Mar 15, 2023 Direct
transaction PRTA Ordinary Shares, par value $0.01 per share Sale -$289K -6K -50% $48.16 6K Mar 15, 2023 Direct F1, F2
transaction PRTA Ordinary Shares, par value $0.01 per share Sale -$292K -6K -100% $48.66 0 Mar 15, 2023 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PRTA Stock Option (Right to Buy) Options Exercise $0 -12K -5.41% $0.00 210K Mar 15, 2023 Ordinary Shares 12K $24.90 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2 The transaction was executed in multiple trades in prices ranging from $47.43 to $48.42, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in footnotes 2 through 3 of this Form 4.
F3 The transaction was executed in multiple trades in prices ranging from $48.44 to $49.06, inclusive.
F4 The shares subject to the option vested and became exercisable as to 25% of the total number of shares subject to the option on April 5, 2022, and vest and become exercisable with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.